Team Metabolic Health Alzheimer’s causes a gradual decline in memory, thinking, behaviour, and social skills, and it is the most common cause of dementia. According to the new study published in the journal Alzheimer’s & Dementia on Thursday, semaglutide was found to significantly lower the risk of developing AD compared to other diabetes medicines. Specifically, […]

Team Metabolic Health Watch This Video Credit: PBS News

Team Metabolic Health Models suggest societal upheaval from anti-obesity medicines — but impacts are hard to predict. Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left more money in people’s wallets. Lighter passengers are saving airlines 100 million litres of fuel each […]

Team Metabolic Health Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the weight-loss medication, a speaker reported. The SURMOUNT-1 trial was a randomized, double-blind, placebo-controlled study for which patients with overweight plus one weight-related comorbidity or obesity and without diabetes […]

Team Metabolic Health Danish biotechnology company Zealand Pharma (ZELA.CO), said on Thursday it expected to initiate a so-called Phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024. “We look forward to initiating a large, comprehensive Phase 2b trial very soon and are now exploring collaboration opportunities with potential partners,” […]

Team Metabolic Health A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss drug in Hong Kong as early as the end […]

Finding to be extremely effective in treating risk factors for stroke, American Stroke Association incorporates the important new class of drug GLP-1 agonists. Team Metabolic Health The American Stroke Association has updated its guidelines on stroke risk reduction for the first time since 2014. In their recommendations, the ASA urges healthcare professionals to carefully screen […]

Team Metabolic Health Given their effects on various organs, they could potentially help you remain functional “New diabetes drugs may delay ageing” made headlines across the media. The reference was to a study using glucagon-like peptide receptor agonist (GLP1RA), which mimics the hormone incretin to regulate appetite and blood glucose levels. Semaglutide, popularly known as […]

Team Metabolic Health Credit: You Tube Channel 60 Minutes

Team Metabolic Health AstraZeneca (AZN.L), opens new tab said on Monday its experimental weight-loss pill, licensed a year ago from China’s Eccogene for up to $2 billion, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class. Sharon Barr, executive vice president of biopharmaceuticals R&D, said AstraZeneca had […]

Team Metabolic Health Popular weight-loss drug Wegovy maker Novo Nordisk (NOVOb.CO) expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said. The company is still “evaluating” the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo’s India Managing […]

Team Metabolic Health Novo Nordisk (NOVOb.CO), opens new tab said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss. Martin Holst Lange, Novo Nordisk’s head of development, made the […]

Team Metabolic Health Novo Nordisk (NOVOb.CO), opens new tab is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday. “In our guidance for the full year, you can assume that there is a step up in the fourth quarter […]

Team Metabolic Health New research highlights the potential for weight-loss medication to ease arthritis symptoms, offering hope for improved mobility and pain relief.  In a recent study published in The New England Journal of Medicine, researchers used a 68-week-long, extensive (61 centers across 11 countries), randomized clinical trial to evaluate Semaglutide’s pain- and weight-relieving performance in overweight arthritis […]

Team Metabolic Health Semaglutide linked to 40-70% lower risk of first-time Alzheimer’s diagnosis in type 2 diabetes patients compared to other antidiabetic medications.  A recent Alzheimer’s and Dementia study uses real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s disease (AD). Could semaglutide prevent AD? In 2014, approximately 6.9 million American […]